EP2773207 - AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 11.01.2019 Database last updated on 15.06.2024 | |
Former | The patent has been granted Status updated on 02.02.2018 | ||
Former | Grant of patent is intended Status updated on 20.09.2017 | ||
Former | Examination is in progress Status updated on 14.12.2016 | Most recent event Tooltip | 10.07.2020 | Lapse of the patent in a contracting state New state(s): IS | published on 12.08.2020 [2020/33] | Applicant(s) | For all designated states Merck Sharp & Dohme Corp. 126 East Lincoln Avenue Rahway, NJ 07065-0907 / US | [2014/37] | Inventor(s) | 01 /
SEGANISH, W. Michael 126 East Lincoln Avenue Rahway, New Jersey 07065-0907 / US | 02 /
BRUMFIELD, Stephanie Nicole 126 East Lincoln Avenue Rahway, New Jersey 07065-0907 / US | 03 /
LIM, Jongwon 33 Avenue Louis Pasteur Boston, Massachusetts 02115-5727 / US | 04 /
MATASI, Julius, J. 16 Putnam Road Monmouth Junction, New Jersey 08852 / US | 05 /
MCELROY, William, T. 126 East Lincoln Avenue Rahway, New Jersey 07065-0907 / US | 06 /
TULSHIAN, Deen, B. 4 Saddle Ridge Drive Lebanon, New jersey 08833 / US | 07 /
LAVEY, Brian, J. 55 Bradford Street New Providence, New Jersey 07974 / US | 08 /
ALTMAN, Michael, D. 33 Avenue Louis Pasteur Boston, Massachusetts 02115-5727 / US | 09 /
GIBEAU, Craig, R. 33 Avenue Louis Pasteur Boston, Massachusetts 02115-5727 / US | 10 /
LAMPE, John William 33 Avenue Louis Pasteur Boston, Massachusetts 02115-5727 / US | 11 /
METHOT, Joey 33 Avenue Louis Pasteur Boston, Massachusetts 02115-5727 / US | 12 /
ZHU, Liang 33 Avenue Louis Pasteur Boston, Massachusetts 02115-5727 / US | [2015/13] |
Former [2014/37] | 01 /
SEGANISH, W. Michael 126 East Lincoln Avenue Rahway, New Jersey 07065-0907 / US | ||
02 /
BRUMFIELD, Stephanie Nicole 126 East Lincoln Avenue Rahway, New Jersey 07065-0907 / US | |||
03 /
LIM, Jongwon 33 Avenue Louis Pasteur Boston, Massachusetts 02115-5727 / US | |||
04 /
MATASI, Julius, J. 16 Putnam Road Monmouth Junction, New Jersey 08852 / US | |||
05 /
MCELROY, William, T. 126 East Lincoln Avenue Rahway, New Jersey 07065-0907 / US | |||
06 /
TULSHIAN, Dean, B. 4 Saddle Ridge Drive Lebanon, New jersey 08833 / US | |||
07 /
LAVEY, Brian, J. 55 Bradford Street New Providence, New Jersey 07974 / US | |||
08 /
ALTMAN, Michael, D. 33 Avenue Louis Pasteur Boston, Massachusetts 02115-5727 / US | |||
09 /
GIBEAU, Craig, R. 33 Avenue Louis Pasteur Boston, Massachusetts 02115-5727 / US | |||
10 /
LAMPE, John William 33 Avenue Louis Pasteur Boston, Massachusetts 02115-5727 / US | |||
11 /
METHOT, Joey 33 Avenue Louis Pasteur Boston, Massachusetts 02115-5727 / US | |||
12 /
ZHU, Liang 33 Avenue Louis Pasteur Boston, Massachusetts 02115-5727 / US | Representative(s) | Jaap, David Robert Merck Sharp & Dohme Corp. 120 Moorgate London, EC2M 6UR / GB | [N/P] |
Former [2014/37] | Jaap, David Robert Merck & Co., Inc. Patent Department Hertford Road Hoddesdon, Herts EN11 9BU / GB | Application number, filing date | 12845873.4 | 26.10.2012 | [2018/10] | WO2012US62016 | Priority number, date | US201161553621P | 31.10.2011 Original published format: US 201161553621 P | [2014/37] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2013066729 | Date: | 10.05.2013 | Language: | EN | [2013/19] | Type: | A1 Application with search report | No.: | EP2773207 | Date: | 10.09.2014 | Language: | EN | The application published by WIPO in one of the EPO official languages on 10.05.2013 takes the place of the publication of the European patent application. | [2014/37] | Type: | B1 Patent specification | No.: | EP2773207 | Date: | 07.03.2018 | Language: | EN | [2018/10] | Search report(s) | International search report - published on: | US | 10.05.2013 | (Supplementary) European search report - dispatched on: | EP | 01.06.2015 | Classification | IPC: | A61K31/5377, C07D401/04, C07D417/04, C07D413/14, C07D491/08, C07D491/10 | [2015/27] | CPC: |
C07D417/04 (EP,US);
A61K31/513 (EP,US);
A61K31/5377 (EP,US);
A61K45/06 (US);
C07D401/04 (EP,US);
C07D401/14 (EP,US);
C07D403/12 (EP,US);
C07D413/14 (EP,US);
C07D417/14 (EP,US);
C07D453/02 (EP,US);
C07D471/08 (EP,US);
C07D487/10 (EP,US);
C07D491/08 (EP,US);
C07D491/10 (EP,US);
C07D491/107 (EP,US);
|
Former IPC [2014/37] | A01N43/54 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/37] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | AMINOPYRIMIDINONE ALS INTERLEUKINREZEPTOR-ASSOZIIERTE KINASEINHIBITOREN | [2014/37] | English: | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | [2014/37] | French: | AMINOPYRIMIDINONES EN TANT QU'INHIBITEURS DE KINASES ASSOCIÉES AU RÉCEPTEUR DE L'INTERLEUKINE | [2014/37] | Entry into regional phase | 02.06.2014 | National basic fee paid | 02.06.2014 | Search fee paid | 02.06.2014 | Designation fee(s) paid | 02.06.2014 | Examination fee paid | Examination procedure | 02.06.2014 | Examination requested [2014/37] | 11.12.2015 | Amendment by applicant (claims and/or description) | 12.05.2016 | Despatch of a communication from the examining division (Time limit: M04) | 22.09.2016 | Reply to a communication from the examining division | 02.12.2016 | Despatch of a communication from the examining division (Time limit: M04) | 10.04.2017 | Reply to a communication from the examining division | 21.09.2017 | Communication of intention to grant the patent | 22.01.2018 | Fee for grant paid | 22.01.2018 | Fee for publishing/printing paid | 22.01.2018 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 12.05.2016 | Opposition(s) | 10.12.2018 | No opposition filed within time limit [2019/07] | Fees paid | Renewal fee | 07.10.2014 | Renewal fee patent year 03 | 07.10.2015 | Renewal fee patent year 04 | 07.10.2016 | Renewal fee patent year 05 | 10.10.2017 | Renewal fee patent year 06 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 26.10.2012 | AL | 07.03.2018 | AT | 07.03.2018 | CY | 07.03.2018 | CZ | 07.03.2018 | DK | 07.03.2018 | EE | 07.03.2018 | ES | 07.03.2018 | FI | 07.03.2018 | HR | 07.03.2018 | IT | 07.03.2018 | LT | 07.03.2018 | LV | 07.03.2018 | MC | 07.03.2018 | MK | 07.03.2018 | NL | 07.03.2018 | PL | 07.03.2018 | RO | 07.03.2018 | RS | 07.03.2018 | SE | 07.03.2018 | SI | 07.03.2018 | SK | 07.03.2018 | SM | 07.03.2018 | TR | 07.03.2018 | BG | 07.06.2018 | NO | 07.06.2018 | GR | 08.06.2018 | IS | 07.07.2018 | PT | 09.07.2018 | IE | 26.10.2018 | LU | 26.10.2018 | MT | 26.10.2018 | BE | 31.10.2018 | CH | 31.10.2018 | LI | 31.10.2018 | [2020/33] |
Former [2020/31] | HU | 26.10.2012 | |
AL | 07.03.2018 | ||
AT | 07.03.2018 | ||
CY | 07.03.2018 | ||
CZ | 07.03.2018 | ||
DK | 07.03.2018 | ||
EE | 07.03.2018 | ||
ES | 07.03.2018 | ||
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
IT | 07.03.2018 | ||
LT | 07.03.2018 | ||
LV | 07.03.2018 | ||
MC | 07.03.2018 | ||
MK | 07.03.2018 | ||
NL | 07.03.2018 | ||
PL | 07.03.2018 | ||
RO | 07.03.2018 | ||
RS | 07.03.2018 | ||
SE | 07.03.2018 | ||
SI | 07.03.2018 | ||
SK | 07.03.2018 | ||
SM | 07.03.2018 | ||
TR | 07.03.2018 | ||
BG | 07.06.2018 | ||
NO | 07.06.2018 | ||
GR | 08.06.2018 | ||
PT | 09.07.2018 | ||
IE | 26.10.2018 | ||
LU | 26.10.2018 | ||
MT | 26.10.2018 | ||
BE | 31.10.2018 | ||
CH | 31.10.2018 | ||
LI | 31.10.2018 | ||
Former [2020/30] | HU | 26.10.2012 | |
AL | 07.03.2018 | ||
AT | 07.03.2018 | ||
CY | 07.03.2018 | ||
CZ | 07.03.2018 | ||
DK | 07.03.2018 | ||
EE | 07.03.2018 | ||
ES | 07.03.2018 | ||
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
IT | 07.03.2018 | ||
LT | 07.03.2018 | ||
LV | 07.03.2018 | ||
MC | 07.03.2018 | ||
NL | 07.03.2018 | ||
PL | 07.03.2018 | ||
RO | 07.03.2018 | ||
RS | 07.03.2018 | ||
SE | 07.03.2018 | ||
SI | 07.03.2018 | ||
SK | 07.03.2018 | ||
SM | 07.03.2018 | ||
TR | 07.03.2018 | ||
BG | 07.06.2018 | ||
NO | 07.06.2018 | ||
GR | 08.06.2018 | ||
PT | 09.07.2018 | ||
IE | 26.10.2018 | ||
LU | 26.10.2018 | ||
MT | 26.10.2018 | ||
BE | 31.10.2018 | ||
CH | 31.10.2018 | ||
LI | 31.10.2018 | ||
Former [2020/16] | AL | 07.03.2018 | |
AT | 07.03.2018 | ||
CY | 07.03.2018 | ||
CZ | 07.03.2018 | ||
DK | 07.03.2018 | ||
EE | 07.03.2018 | ||
ES | 07.03.2018 | ||
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
IT | 07.03.2018 | ||
LT | 07.03.2018 | ||
LV | 07.03.2018 | ||
MC | 07.03.2018 | ||
NL | 07.03.2018 | ||
PL | 07.03.2018 | ||
RO | 07.03.2018 | ||
RS | 07.03.2018 | ||
SE | 07.03.2018 | ||
SI | 07.03.2018 | ||
SK | 07.03.2018 | ||
SM | 07.03.2018 | ||
TR | 07.03.2018 | ||
BG | 07.06.2018 | ||
NO | 07.06.2018 | ||
GR | 08.06.2018 | ||
PT | 09.07.2018 | ||
IE | 26.10.2018 | ||
LU | 26.10.2018 | ||
MT | 26.10.2018 | ||
BE | 31.10.2018 | ||
CH | 31.10.2018 | ||
LI | 31.10.2018 | ||
Former [2020/08] | AL | 07.03.2018 | |
AT | 07.03.2018 | ||
CY | 07.03.2018 | ||
CZ | 07.03.2018 | ||
DK | 07.03.2018 | ||
EE | 07.03.2018 | ||
ES | 07.03.2018 | ||
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
IT | 07.03.2018 | ||
LT | 07.03.2018 | ||
LV | 07.03.2018 | ||
MC | 07.03.2018 | ||
NL | 07.03.2018 | ||
PL | 07.03.2018 | ||
RO | 07.03.2018 | ||
RS | 07.03.2018 | ||
SE | 07.03.2018 | ||
SI | 07.03.2018 | ||
SK | 07.03.2018 | ||
SM | 07.03.2018 | ||
BG | 07.06.2018 | ||
NO | 07.06.2018 | ||
GR | 08.06.2018 | ||
PT | 09.07.2018 | ||
IE | 26.10.2018 | ||
LU | 26.10.2018 | ||
MT | 26.10.2018 | ||
BE | 31.10.2018 | ||
CH | 31.10.2018 | ||
LI | 31.10.2018 | ||
Former [2019/48] | AL | 07.03.2018 | |
AT | 07.03.2018 | ||
CY | 07.03.2018 | ||
CZ | 07.03.2018 | ||
DK | 07.03.2018 | ||
EE | 07.03.2018 | ||
ES | 07.03.2018 | ||
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
IT | 07.03.2018 | ||
LT | 07.03.2018 | ||
LV | 07.03.2018 | ||
MC | 07.03.2018 | ||
NL | 07.03.2018 | ||
PL | 07.03.2018 | ||
RO | 07.03.2018 | ||
RS | 07.03.2018 | ||
SE | 07.03.2018 | ||
SI | 07.03.2018 | ||
SK | 07.03.2018 | ||
SM | 07.03.2018 | ||
BG | 07.06.2018 | ||
NO | 07.06.2018 | ||
GR | 08.06.2018 | ||
PT | 09.07.2018 | ||
IE | 26.10.2018 | ||
LU | 26.10.2018 | ||
BE | 31.10.2018 | ||
CH | 31.10.2018 | ||
LI | 31.10.2018 | ||
Former [2019/40] | AL | 07.03.2018 | |
AT | 07.03.2018 | ||
CY | 07.03.2018 | ||
CZ | 07.03.2018 | ||
DK | 07.03.2018 | ||
EE | 07.03.2018 | ||
ES | 07.03.2018 | ||
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
IT | 07.03.2018 | ||
LT | 07.03.2018 | ||
LV | 07.03.2018 | ||
MC | 07.03.2018 | ||
NL | 07.03.2018 | ||
PL | 07.03.2018 | ||
RO | 07.03.2018 | ||
RS | 07.03.2018 | ||
SE | 07.03.2018 | ||
SI | 07.03.2018 | ||
SK | 07.03.2018 | ||
SM | 07.03.2018 | ||
BG | 07.06.2018 | ||
NO | 07.06.2018 | ||
GR | 08.06.2018 | ||
PT | 09.07.2018 | ||
LU | 26.10.2018 | ||
BE | 31.10.2018 | ||
CH | 31.10.2018 | ||
LI | 31.10.2018 | ||
Former [2019/38] | AL | 07.03.2018 | |
AT | 07.03.2018 | ||
CY | 07.03.2018 | ||
CZ | 07.03.2018 | ||
DK | 07.03.2018 | ||
EE | 07.03.2018 | ||
ES | 07.03.2018 | ||
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
IT | 07.03.2018 | ||
LT | 07.03.2018 | ||
LV | 07.03.2018 | ||
MC | 07.03.2018 | ||
NL | 07.03.2018 | ||
PL | 07.03.2018 | ||
RO | 07.03.2018 | ||
RS | 07.03.2018 | ||
SE | 07.03.2018 | ||
SI | 07.03.2018 | ||
SK | 07.03.2018 | ||
SM | 07.03.2018 | ||
BG | 07.06.2018 | ||
NO | 07.06.2018 | ||
GR | 08.06.2018 | ||
PT | 09.07.2018 | ||
LU | 26.10.2018 | ||
BE | 31.10.2018 | ||
Former [2019/30] | AL | 07.03.2018 | |
AT | 07.03.2018 | ||
CY | 07.03.2018 | ||
CZ | 07.03.2018 | ||
DK | 07.03.2018 | ||
EE | 07.03.2018 | ||
ES | 07.03.2018 | ||
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
IT | 07.03.2018 | ||
LT | 07.03.2018 | ||
LV | 07.03.2018 | ||
MC | 07.03.2018 | ||
NL | 07.03.2018 | ||
PL | 07.03.2018 | ||
RO | 07.03.2018 | ||
RS | 07.03.2018 | ||
SE | 07.03.2018 | ||
SI | 07.03.2018 | ||
SK | 07.03.2018 | ||
SM | 07.03.2018 | ||
BG | 07.06.2018 | ||
NO | 07.06.2018 | ||
GR | 08.06.2018 | ||
PT | 09.07.2018 | ||
LU | 26.10.2018 | ||
Former [2019/28] | AL | 07.03.2018 | |
AT | 07.03.2018 | ||
CY | 07.03.2018 | ||
CZ | 07.03.2018 | ||
DK | 07.03.2018 | ||
EE | 07.03.2018 | ||
ES | 07.03.2018 | ||
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
IT | 07.03.2018 | ||
LT | 07.03.2018 | ||
LV | 07.03.2018 | ||
MC | 07.03.2018 | ||
NL | 07.03.2018 | ||
PL | 07.03.2018 | ||
RO | 07.03.2018 | ||
RS | 07.03.2018 | ||
SE | 07.03.2018 | ||
SI | 07.03.2018 | ||
SK | 07.03.2018 | ||
SM | 07.03.2018 | ||
BG | 07.06.2018 | ||
NO | 07.06.2018 | ||
GR | 08.06.2018 | ||
PT | 09.07.2018 | ||
Former [2019/13] | AL | 07.03.2018 | |
AT | 07.03.2018 | ||
CY | 07.03.2018 | ||
CZ | 07.03.2018 | ||
DK | 07.03.2018 | ||
EE | 07.03.2018 | ||
ES | 07.03.2018 | ||
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
IT | 07.03.2018 | ||
LT | 07.03.2018 | ||
LV | 07.03.2018 | ||
NL | 07.03.2018 | ||
PL | 07.03.2018 | ||
RO | 07.03.2018 | ||
RS | 07.03.2018 | ||
SE | 07.03.2018 | ||
SI | 07.03.2018 | ||
SK | 07.03.2018 | ||
SM | 07.03.2018 | ||
BG | 07.06.2018 | ||
NO | 07.06.2018 | ||
GR | 08.06.2018 | ||
PT | 09.07.2018 | ||
Former [2019/08] | AL | 07.03.2018 | |
AT | 07.03.2018 | ||
CY | 07.03.2018 | ||
CZ | 07.03.2018 | ||
DK | 07.03.2018 | ||
EE | 07.03.2018 | ||
ES | 07.03.2018 | ||
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
IT | 07.03.2018 | ||
LT | 07.03.2018 | ||
LV | 07.03.2018 | ||
NL | 07.03.2018 | ||
PL | 07.03.2018 | ||
RO | 07.03.2018 | ||
RS | 07.03.2018 | ||
SE | 07.03.2018 | ||
SK | 07.03.2018 | ||
SM | 07.03.2018 | ||
BG | 07.06.2018 | ||
NO | 07.06.2018 | ||
GR | 08.06.2018 | ||
PT | 09.07.2018 | ||
Former [2019/03] | AL | 07.03.2018 | |
AT | 07.03.2018 | ||
CY | 07.03.2018 | ||
CZ | 07.03.2018 | ||
EE | 07.03.2018 | ||
ES | 07.03.2018 | ||
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
IT | 07.03.2018 | ||
LT | 07.03.2018 | ||
LV | 07.03.2018 | ||
NL | 07.03.2018 | ||
PL | 07.03.2018 | ||
RO | 07.03.2018 | ||
RS | 07.03.2018 | ||
SE | 07.03.2018 | ||
SK | 07.03.2018 | ||
SM | 07.03.2018 | ||
BG | 07.06.2018 | ||
NO | 07.06.2018 | ||
GR | 08.06.2018 | ||
PT | 09.07.2018 | ||
Former [2018/52] | AL | 07.03.2018 | |
AT | 07.03.2018 | ||
CY | 07.03.2018 | ||
CZ | 07.03.2018 | ||
EE | 07.03.2018 | ||
ES | 07.03.2018 | ||
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
IT | 07.03.2018 | ||
LT | 07.03.2018 | ||
LV | 07.03.2018 | ||
NL | 07.03.2018 | ||
PL | 07.03.2018 | ||
RO | 07.03.2018 | ||
RS | 07.03.2018 | ||
SE | 07.03.2018 | ||
SK | 07.03.2018 | ||
SM | 07.03.2018 | ||
BG | 07.06.2018 | ||
NO | 07.06.2018 | ||
GR | 08.06.2018 | ||
Former [2018/50] | AL | 07.03.2018 | |
AT | 07.03.2018 | ||
CY | 07.03.2018 | ||
CZ | 07.03.2018 | ||
EE | 07.03.2018 | ||
ES | 07.03.2018 | ||
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
IT | 07.03.2018 | ||
LT | 07.03.2018 | ||
LV | 07.03.2018 | ||
NL | 07.03.2018 | ||
PL | 07.03.2018 | ||
RO | 07.03.2018 | ||
RS | 07.03.2018 | ||
SE | 07.03.2018 | ||
SK | 07.03.2018 | ||
BG | 07.06.2018 | ||
NO | 07.06.2018 | ||
GR | 08.06.2018 | ||
Former [2018/47] | AL | 07.03.2018 | |
CY | 07.03.2018 | ||
ES | 07.03.2018 | ||
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
IT | 07.03.2018 | ||
LT | 07.03.2018 | ||
LV | 07.03.2018 | ||
NL | 07.03.2018 | ||
RS | 07.03.2018 | ||
SE | 07.03.2018 | ||
BG | 07.06.2018 | ||
NO | 07.06.2018 | ||
GR | 08.06.2018 | ||
Former [2018/46] | AL | 07.03.2018 | |
CY | 07.03.2018 | ||
ES | 07.03.2018 | ||
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
LT | 07.03.2018 | ||
LV | 07.03.2018 | ||
NL | 07.03.2018 | ||
RS | 07.03.2018 | ||
SE | 07.03.2018 | ||
BG | 07.06.2018 | ||
NO | 07.06.2018 | ||
GR | 08.06.2018 | ||
Former [2018/45] | CY | 07.03.2018 | |
ES | 07.03.2018 | ||
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
LT | 07.03.2018 | ||
LV | 07.03.2018 | ||
NL | 07.03.2018 | ||
RS | 07.03.2018 | ||
SE | 07.03.2018 | ||
BG | 07.06.2018 | ||
NO | 07.06.2018 | ||
GR | 08.06.2018 | ||
Former [2018/40] | CY | 07.03.2018 | |
ES | 07.03.2018 | ||
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
LT | 07.03.2018 | ||
LV | 07.03.2018 | ||
RS | 07.03.2018 | ||
SE | 07.03.2018 | ||
BG | 07.06.2018 | ||
NO | 07.06.2018 | ||
GR | 08.06.2018 | ||
Former [2018/39] | CY | 07.03.2018 | |
ES | 07.03.2018 | ||
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
LT | 07.03.2018 | ||
LV | 07.03.2018 | ||
RS | 07.03.2018 | ||
SE | 07.03.2018 | ||
NO | 07.06.2018 | ||
GR | 08.06.2018 | ||
Former [2018/37] | CY | 07.03.2018 | |
ES | 07.03.2018 | ||
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
LT | 07.03.2018 | ||
NO | 07.06.2018 | ||
GR | 08.06.2018 | ||
Former [2018/36] | CY | 07.03.2018 | |
ES | 07.03.2018 | ||
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
LT | 07.03.2018 | ||
NO | 07.06.2018 | ||
Former [2018/35] | CY | 07.03.2018 | |
FI | 07.03.2018 | ||
HR | 07.03.2018 | ||
LT | 07.03.2018 | ||
NO | 07.06.2018 | Documents cited: | Search | [X]WO2009136995 (PORTOLA PHARM INC [US], et al) [X] 1-3,9-13 * Page 59, third last compound; page 60, last compound. * * page 1, paragraph 0004 * * claim 55 *; | [X]EP1184376 (YAMANOUCHI PHARMA CO LTD [JP]) [X] 1-3,9-13 * page 9, paragraph 0051 * * tables 1,2,10 * * claims 1,4 *; | [X]EP0178178 (WARNER LAMBERT CO [US]) [X] 1-3 * compounds IV, IVa-b * * examples 1-4,10-12A * * tables 1-2 * * claims 16,19 *; | [X]EP0156559 (WARNER LAMBERT CO [US]) [X] 1-3 * compound 7 * * examples 1,1A *; | [X]FR1381646 (WELLCOME FOUND) [X] 1-3 * example 2 *; | [X]WO8404040 (UNIV SOUTH ALABAMA [US]) [X] 1-3 * shcem I, compound IV * * examples I, II *; | [A]WO2010112210 (CELLZOME AG [DE], et al) [A] 1-13 * page 1, paragraph 1 * * page 25, line 7 - line 8 * * claim 1 *; | [A]WO2008030579 (BIOGEN IDEC INC [US], et al) [A] 1-13 * page 1, paragraph 001 * * page 47, paragraph 0151 * * claims 1,31 * | [X] - VISHWAKARMA J N ET AL, "Reactions of Polarized Keten S,N-Acetals with Guanidine: A Facile General Route to Novel 5,6-Substituted 2-Amino-4-N-alkyl/aryl/N-azacycloalkylaminopyrimidines", INDIAN JOURNAL OF CHEMISTRY. SECTION B, COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (C S I R), IN, (19850101), vol. 24, ISSN 0376-4699, pages 466 - 471, XP009162452 [X] 1-7 * compound 13a * DOI: http://dx.doi.org/10.1002/chin.198546194 | International search | [Y]WO2010068863 (CYSTIC FIBROSIS FOUNDATION THE [US], et al); | [Y]US2005038010 (CAO GUO-QIANG [US], et al); | [Y]US4910204 (WALKER FREDERICK J [US], et al); | [Y]US6649604 (SPOHR ULRIKE D [US], et al); | [Y]US2009215801 (ALBERT JEFFREY [US], et al); | [Y]WO8900423 (PFIZER [US]); | [A]US7429594 (LIU LONGBIN [US], et al); | [A]US6420385 (SPOHR ULRIKE D [US], et al); | [A]US6096753 (SPOHR ULRIKE D [US], et al) | [Y] - WANG ET AL., "IRAK-4 Inhibitors for Inflammation", CURRENT TOPICS IN MEDICINAL CHEMISTRY, (2009), vol. 9, pages 724 - 737, XP055067855 DOI: http://dx.doi.org/10.2174/156802609789044407 | [A] - LI ET AL., "IRAK-4: A novel member of the IRAK family with the properties of an IRAK-kinase", PNAS, (2002), vol. 99, no. 8, pages 5567 - 5572, XP002268506 DOI: http://dx.doi.org/10.1073/pnas.082100399 | Examination | DE2516118 | - MATSUURA SADAO, "Structure of the pteridine glycoside from Aspergillus oryzae", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, (19720101), vol. 45, no. 2, XP055322851 | - Wolfgang Pfleiderer ET AL, "Uber die Synthese und Struktur N-8-substituierter Pterine und Lumazine", (19710101), pages 2273 - 2292, CHEMISCHE BERICHTE, URL: http://onlinelibrary.wiley.com/store/10.1002/cber.19711040731/asset/19711040731_ftp.pdf?v=1&t=ivwhwkpy&s=b008e1459d63f47792c7dfaec8b444587c1c1dad, XP055322857 | by applicant | US5474995 | US5861419 | US6001843 | US6020343 | US5409944 | US5436265 | US5536752 | US5550142 | US5604260 | US5698584 | US5710140 | WO9415932 | US5344991 | US5134142 | US5380738 | US5393790 | US5466823 | US5633272 | US5932598 | WO2011029046 | WO2010016005 | - LI, S. ET AL., "IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase", PROC NATL ACAD SCI USA., (20020416), vol. 99, no. 8, pages 5567 - 72 | - SUZUKI, N ET AL., "Severe impairment of interleukin-1 and Toll-like receptor signaling in mice lacking IRAK-4", NATURE, (2002), vol. 416, pages 750 - 756 | - PICARD, C. ET AL., "Pyogenic bacterial infections in humans with IRAK-4 deficiency", SCIENCE, (2003), vol. 299, pages 2076 - 2079 | - WANG ET AL., "IRAK-4 Inhibitors for Inflammation", CURRENT TOPICS IN MEDICINAL CHEMISTRY, (2009), vol. 9, pages 724 - 737 | - E.L. ELIEL; S.H. WILEN, Stereochemistry of Carbon Compounds, JOHN WILEY & SONS, (1994), pages 1119 - 1190 | - BERG ET AL., "Pharmaceutical Salts", J. PHARM. SCI., (1977), vol. 66, pages 1 - 19 | - GIRIJAVALLABHAN, V. ET AL., J. ORG. CHEM., (2011), vol. 76, page 6442 |